Monitor for patient enrollment updates and interim data readouts from the NEPTUNE trial, which could serve as binary catalysts for the stock. The lack of approved NCP treatments amplifies the potential upside if efficacy data are positive.
Price Chart
Executive Summary
OKYO Pharma announced first patients enrolled in the Phase 3 NEPTUNE pivotal trial of urcosimod for neuropathic corneal pain (NCP), a condition with no FDA-approved treatment. This is a key clinical milestone for the company's lead candidate, but no efficacy or safety data were reported.
Key Facts
- First patients enrolled in Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain (NCP)
- Trial is a registrational study designed per FDA guidance
- Primary endpoint: change from baseline in ocular pain VAS score at 12 weeks
- Multi-site trial across US and Europe (Italy, Spain, France)
- No FDA-approved therapy currently exists for NCP
Financial Impact
No financial figures disclosed; milestone de-risks lead pipeline candidate urcosimod
Risk Factors
- Clinical trial may fail to meet primary endpoint
- No revenue or financial data in filing; cash runway and dilution risk remain key concerns
- Competing NCP therapies in development could emerge
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-045836 |
| Exhibit: ex99-1.htm | 0001493152-26-045836 |
| Document: 0001493152-26-045836-index-headers.html | 0001493152-26-045836 |
| Document: 0001493152-26-045836-index.html | 0001493152-26-045836 |
| Document: 0001493152-26-045836.txt | 0001493152-26-045836 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 6-K | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.44 (−1.37%) |
Oct 6, 2026 20d ago | Press Release | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.44 (−1.37%) |
Sep 29, 2026 27d ago | 6-K | $1.36 $1.29 | ▼ −5.15% | ▼ −4.94% | $1.44 (+5.88%) |
Sep 8, 2026 6w ago | 6-K | $1.53 $1.45 | ▼ −5.23% | ▼ −4.76% | $1.44 (−5.88%) |
Aug 7, 2026 11w ago | Insider Cluster | $1.57 $1.52 | ▼ −3.18% | ▼ −2.87% | $1.44 (−8.28%) |
Jul 28, 2026 12w ago | 6-K | $1.64 $1.64 | · 0.00% | ▲ +1.54% | $1.44 (−12.20%) |
Jul 27, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▼ −0.24% | $1.44 (−12.20%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.44 (−2.70%) |
Jul 23, 2026 13w ago | Press Release | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.44 (−2.70%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.44 (−2.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers